Apellis Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Apellis Pharmaceuticals

07/05/2024 14:31

* Apellis Pharmaceuticals Inc  APLS.OQ  reported a quarterly
adjusted loss of 42 cents​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of $-1.56.  The mean expectation of
sixteen analysts for the quarter was for a loss of 52 cents per
share. Wall Street expected results to range from -83 cents
to -14 cents per share.
    * Revenue rose 284.3% to $172.33 million from a year ago;
analysts
expected $163.35 million. 
    * Apellis Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 54 cents​.
    * The company reported a quarterly loss of $66.42 million.
    * Apellis Pharmaceuticals Inc shares had fallen by 17.0%
this
quarter and lost 18.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.8%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Apellis
Pharmaceuticals Inc is $83.00 

This summary was machine generated from LSEG data May 7 at 01:31
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.52          -0.42          Beat
 Dec. 31 2023      -0.69          -0.73          Missed
 Sep. 30 2023      -0.86          -1.17          Missed
 Jun. 30 2023      -1.32          -1.02          Beat